Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory Prostate Cancer Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01347788
What this trial is testing

Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Adenocarcinoma
Massachusetts General Hospital 34
Testing effectiveness (Phase 2)Looking for participantsNCT06267729
What this trial is testing

Study of AZD0754 in Participants With Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
AstraZeneca 60
Testing effectiveness (Phase 2)Study completedNCT05655715
What this trial is testing

Checkpoint Inhibitors and SBRT for MCRPC

Who this might be right for
Prostate Cancer MetastaticCastrate Resistant Prostate CancerMetastatic Castration-resistant Prostate Cancer+1 more
Herlev and Gentofte Hospital 90
Testing effectiveness (Phase 2)Looking for participantsNCT06288113
What this trial is testing

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Who this might be right for
Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Jonsson Comprehensive Cancer Center 40
Testing effectiveness (Phase 2)Ended earlyNCT02431260
What this trial is testing

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Who this might be right for
Solid Tumors and Hematologic Malignancy
Incyte Corporation 69
Early research (Phase 1)UnknownNCT00009750
What this trial is testing

Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
University of California, Davis
Early research (Phase 1)Not Yet RecruitingNCT07423117
What this trial is testing

ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy

Who this might be right for
Metastatic Castration-resistant Prostate CancerNon-small Cell Lung CancerTriple Negative Breast Cancer+1 more
IntoCell, Inc 102
Testing effectiveness (Phase 2)Active Not RecruitingNCT05057013
What this trial is testing

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Who this might be right for
Bladder CancerTriple Negative Breast CancerCastration-resistant Prostate Cancer+11 more
Cancer Research UK 81
Early research (Phase 1)Study completedNCT02036918
What this trial is testing

Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Duke University 20
Early research (Phase 1)Looking for participantsNCT07543055
What this trial is testing

BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

Who this might be right for
Prostate Cancer
Regeneron Pharmaceuticals 36
Early research (Phase 1)Ended earlyNCT00933426
What this trial is testing

Lenalidomide and Paclitaxel in Prostate Cancer

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center 17
Not applicableStudy completedNCT02813408
What this trial is testing

Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants

Who this might be right for
Prostatic Neoplasms
Janssen Pharmaceutica N.V., Belgium 226
Large-scale testing (Phase 3)Study completedNCT02043678
What this trial is testing

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

Who this might be right for
Prostatic Neoplasms
Bayer 806
Not applicableLooking for participantsNCT07677267
What this trial is testing

Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Novartis Pharmaceuticals 1,067
Testing effectiveness (Phase 2)Looking for participantsNCT05489211
What this trial is testing

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Who this might be right for
Endometrial CancerGastric CancerMetastatic Castration-resistant Prostate Cancer+4 more
AstraZeneca 454
Testing effectiveness (Phase 2)Ended earlyNCT03207867
What this trial is testing

NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Who this might be right for
NSCLC, Non Small Cell Lung CancerRCC, Renal Cell CancerPancreatic Cancer+7 more
Novartis Pharmaceuticals 315
Testing effectiveness (Phase 2)Study completedNCT03093428
What this trial is testing

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

Who this might be right for
Prostate Cancer
Dana-Farber Cancer Institute 45
Not applicableStudy completedNCT07450157
What this trial is testing

Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 6,448
Testing effectiveness (Phase 2)Study completedNCT02121639
What this trial is testing

Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy

Who this might be right for
Prostate Cancer
University Hospital Southampton NHS Foundation Trust 160
Testing effectiveness (Phase 2)Study completedNCT01881867
What this trial is testing

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+1 more
Fred Hutchinson Cancer Center 54
Next Page